AstraZeneca PLC (AZNCF)
| Market Cap | 251.37B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.31 |
| PE Ratio | 30.30 |
| Forward PE | 16.61 |
| Dividend | 3.13 (1.90%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 11 |
| Average Volume | 5,503 |
| Open | 159.55 |
| Previous Close | 164.50 |
| Day's Range | 159.55 - 164.50 |
| 52-Week Range | 120.64 - 164.50 |
| Beta | 0.15 |
| RSI | 64.99 |
| Earnings Date | Nov 6, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or...
AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy
AstraZeneca (AZN) Study Shows Enhanced Survival with TAGRISSO and Chemotherapy
TN signs MoUs with Hinduja, AstraZeneca
Chennai: State govt represented by chief minister M K Stalin signed a memorandum of understanding (MoU) worth 7,500 crore with UK-based Hinduja Group .
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
French drugmaker Sanofi SA (NASDAQ: SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match inves...
AstraZeneca, Corning And More On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jim Lebenthal , partner at Cerity Partners, named AstraZeneca PLC (NASDAQ: AZN) as his final trade . On Aug. 20, AstraZeneca released complete results from...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Final Trades: AstraZeneca, Corning, the IBIT and the SPHD
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: AstraZeneca, Corning, the IBIT and the SPHD
The Investment Committee give you their top stocks to watch for the second half.
Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success
Mineralys (MLYS) Soars 85% After AstraZeneca's Drug Trial Success
Mineralys surges after late-stage trial data AstraZeneca’s blood pressure drug
AstraZeneca: Buy This Pharma Star Now For Upside Potential
AstraZeneca (AZN) Reports Positive Baxdrostat Trial Results for Hypertension
AstraZeneca (AZN) Reports Positive Baxdrostat Trial Results for Hypertension
AstraZeneca (AZN) Targets Regulatory Approval for Hypertension Drug Baxdrostat
AstraZeneca (AZN) Targets Regulatory Approval for Hypertension Drug Baxdrostat
AstraZeneca is said to seek approval for antihypertensive this year
AstraZeneca PLC (AZN) Announces Positive Phase III Trial Results for Baxdrostat in Hypertension ...
AstraZeneca PLC (AZN) Announces Positive Phase III Trial Results for Baxdrostat in Hypertension Treatment | AZN stock news
AstraZeneca to seek approval for blood pressure drug by year-end
AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a senior company executive said, about a product seen as key to the drugmaker...
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people with uncontrolled high blood pressure.
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit Therapeutics Inc (NASDAQ: SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small ...
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs p...
Polaris Pharmacy Services Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service—The World's First At-Home Nasal Spray Flu Vaccine
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMis...
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca
FibroGen (FGEN) gains over 3% after China approves its sale to AstraZeneca Treasury. Deal set to close by Q3 2025.
Scared of needles? AstraZeneca launches FluMist Home nasal spray delivery
AstraZeneca introduces FluMist Home, offering a needle-free flu vaccine delivered directly to your door. This FDA-approved nasal spray allows adults aged 18-49 and parents of children aged 2-17 to adm...
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery
AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca t...
George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98%
George Soros Exits AstraZeneca PLC, Impacting Portfolio by -3.98%
The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.